The promise of DNA damage response inhibitors for the treatment of glioblastoma

Glioblastoma (GBM), the most aggressive primary brain tumor, has a dismal prognosis. Despite our growing knowledge of genomic and epigenomic alterations in GBM, standard therapies and outcomes have not changed significantly in the past two decades. There is therefore an urgent unmet need to develop...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neurooncol Adv
Egile Nagusiak: Majd, Nazanin K, Yap, Timothy A, Koul, Dimpy, Balasubramaniyan, Veerakumar, Li, Xiaolong, Khan, Sabbir, Gandy, Katilin S, Yung, W K Alfred, de Groot, John F
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2021
Gaiak:
Reviews
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7954093/
https://ncbi.nlm.nih.gov/pubmed/33738447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdab015
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak